MDS Capital
One Vanderbilt Avenue, 26th Floor, New York, NY, 10017, United States
Overview
MDS Capital Corp. was established in 1988 to participate in the financing and development of health-related technologies. Its objective is to become involved with entrepreneurs and scientists who have developed at least the basic concepts and elements of innovative products or services and who require the kinds of financial, managerial and other support MDS Capital Corp. is uniquely suited to provide.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 0
Sector focus
- Biotechnology
- Medical
- Venture Capital
Investment portfolio
- PhageTech
Participated · Equity · Mar 2002
PhageTech, Inc. is a development-stage medical diagnostics company based in Irvine, CA that is building biosensors that use a bacteriophage substrate to detect analytes in urine, blood, and other body fluids. The core product, the PhageTech Biosensor™, was originally developed at the University of California, Irvine with NIH grant support. When paired with a portable reader, the sensor aims to deliver near-patient test results in under one minute, giving physicians real-time data for earlier diagnosis and improved treatment outcomes. The technology targets early detection of cancers as well as a broad range of other diseases. Current efforts are focused on completing product development and securing FDA clearance. Richard Henson serves as CEO, and the company remains pre-commercial with no disclosed revenue or user metrics. The recent capital infusion will fund final engineering, regulatory submissions, and preparation for market entry.
Team
No current team members are available.